Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions - 30/12/22
Abstract |
Background |
Indwelling pleural catheters (IPCs) are a mainstay therapy for malignant pleural effusions (MPEs). Many patients treated with IPCs achieve pleurodesis. We aimed to identify the effect of systemic therapies for non-small cell lung cancer (NSCLC) on IPC removal in patients with associated MPEs.
Methods |
We completed a retrospective cohort study of adult IPC recipients with metastatic NSCLC at the pleural effusion clinic at the Royal Alexandra Hospital from 2009 to 2020. We used logistic regression to assess the rates of IPC removal and Cox regression to assess the time to IPC removal.
Results |
232 patients met inclusion criteria with 248 IPCs reviewed. The overall pleurodesis rate was 42.7% with a median time to pleurodesis of 68 (IQR 38–140) days. In univariate analysis, chemotherapy (OR 1.86, CI 0.99–3.49) and epidermal growth factor receptor (EGFR) targeted therapy (OR 3.81, CI 1.86–7.79) were associated with higher rates of pleurodesis. In multivariate analysis, increased rates of pleurodesis were associated with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤2 (OR 4.82, CI 2.24–10.37) and EGFR targeted therapy (OR 3.87, CI 1.80–8.32). Earlier IPC removal was associated with EGFR targeted therapy in both univariate (HR 1.84, CI 1.20–2.83) and multivariate analysis (HR 1.86, CI 1.19–2.92).
Conclusions |
Treatment with EGFR targeted therapy is associated with increased rates and earlier removal of IPC in patients with NSCLC in our cohort. Further large cohort studies are required to determine if this relationship persists.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Malignant pleural effusions occur in ∼40% of patients with advanced NSCLC. |
• | Malignant pleural effusions are often managed with indwelling pleural catheters. |
• | Lower ECOG is associated with increased rate of pleurodesis. |
• | EGFR targeted therapy is associated with higher rates of and earlier pleurodesis. |
Keywords : Malignant pleural effusion, Indwelling pleural catheter, Non-small cell lung cancer, EGFR targeted Therapy, Immunotherapy
Abbreviations : MPE, IPC, NSCLC, EGFR, ECOG PS
Plan
Vol 206
Article 107093- janvier 2023 Retour au numéro
Article précédent
- Health trajectories in older patients hospitalized for COVID-19: Results from the GeroCovid multicenter study
- Caterina Trevisan, Francesco Tonarelli, Alberto Zucchelli, Ilaria Parrotta, Riccardo Calvani, Alba Malara, Fabio Monzani, Pietro Gareri, Gianluca Zia, Raffaele Antonelli Incalzi, the GeroCovid Acute Wards Working Group
- The clinical features of asthma exacerbations in early-onset and eosinophilic late-onset asthma may differ significantly
- Thomas Rothe, Christophe von Garnier, Pierre-Olivier Bridevaux, Florian Charbonnier, Christian Clarenbach, Pietro Gianella, Anja Jochmann, Lukas Kern, Pavlov Nikolay, Claudia Steurer-Stey, Joerg D Leuppi, members of the SIG Obstructive Lung Diseases of the Swiss Society of Pneumology
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?